africa
sequenti
immun
chines
rhesu
macaqu
antigenspecif
singl
b
cell
sort
mab
demonstr
potent
neutral
activ
pseudo
live
ebola
viru
independ
complement
biochem
singl
particl
em
mutagenesi
analysi
suggest
recogn
novel
epitop
head
target
glycan
cap
subunit
appear
influenc
gp
bind
receptor
treatment
mab
provid
partial
signific
protect
diseas
mous
model
ebola
viru
infect
novel
mab
could
serv
promis
candid
prophylact
therapeut
intervent
ebola
viru
infect
ebolaviru
etiolog
agent
lethal
hemorrhag
fever
human
nonhuman
primat
sinc
discoveri
ebolaviru
caus
frequent
outbreak
across
central
africa
exceedingli
high
mortal
rate
natur
host
current
unknown
ebolaviru
explor
speci
host
across
broader
geograph
frontier
notabl
unpreced
outbreak
west
africa
number
affect
peopl
surpass
previous
record
case
combin
rais
concern
pandem
potenti
pose
seriou
threat
global
health
genet
ebolaviru
isol
far
repres
diverg
evolv
cluster
broadli
classifi
speci
zair
ebov
sudan
sudv
bundibugyo
bdbv
reston
restv
tai
forest
tafv
virus
multipl
lineag
ebov
identifi
increas
phylogenet
genet
divers
outbreak
west
africa
uncertain
whether
observ
genet
divers
caus
consequ
current
epidem
high
mortal
rate
associ
rapid
human
human
transmiss
strongli
argu
effect
therapeut
vaccin
ebov
infect
surfac
glycoprotein
gp
ebov
mediat
viral
entri
serv
main
target
antibodybas
therapi
vaccin
translat
insid
target
cell
gp
cleav
furin
yield
disulphidelink
subunit
assembl
metast
trimer
subunit
respons
cellular
attach
bind
receptor
niemann
pick
wherea
mediat
fusion
viral
cellular
membran
three
subunit
form
chalic
consist
receptor
bind
domain
rbd
glycan
cap
heavili
glycosyl
mucinlik
domain
mld
rbd
sequest
chalic
bowl
glycan
cap
mld
project
rim
chalic
prevent
immun
recognit
wrap
around
form
base
chalic
contain
fusion
loop
well
nand
ctermin
heptad
repeat
region
critic
viral
fusion
viral
entri
gp
undergo
proteolyt
cleavag
endosom
cathepsin
proteas
gener
cleav
gp
gpcl
devoid
glycan
cap
mld
expos
addit
surfac
residu
requir
bind
addit
unedit
gp
gene
encod
solubl
gp
sgp
includ
glycan
cap
lack
mld
shown
sgp
produc
larger
quantiti
gp
replic
may
therefor
act
decoy
bind
neutral
antibodi
complex
gp
structur
insidi
tactic
evad
distract
immun
recognit
may
partial
explain
major
infect
individu
succumb
diseas
fail
gener
strong
neutral
antibodi
natur
infect
recent
signific
progress
made
antibodi
therapi
vaccin
ebov
although
product
yet
receiv
regulatori
approv
particular
monoclon
antibodi
mab
cocktail
instead
singl
mab
confer
protect
nonhuman
primat
passiv
administ
otherwis
lethal
viral
challeng
potent
success
cocktail
includ
consist
human
humanmous
chimer
mab
zmab
consist
murin
mab
zmapp
consist
humanmous
chimer
mab
strikingli
zmapp
demonstr
protect
effect
nonhuman
primat
administ
late
day
post
infect
use
compassion
basi
human
outbreak
epitop
map
mab
well
publish
elsewher
reveal
converg
three
major
site
surfac
gp
includ
glycan
cap
mucinlik
domain
base
gp
subunit
interact
unexpectedli
neutral
mab
target
overlap
epitop
base
gp
neutral
neutral
absenc
complement
bind
glycan
cap
mucinlik
domain
recent
studi
identifi
sever
novel
crossreact
mab
potent
neutral
activ
confer
protect
mous
guinea
pig
monkey
model
need
note
howev
neutral
activ
mab
necessarili
predictor
protect
vivo
mechan
prevent
bud
nascent
viral
particl
infect
cell
fcmediat
function
taken
account
set
rais
neutral
mab
target
gp
ebov
identifi
sequenti
immun
chines
rhesu
macaqu
antigenspecif
singl
b
cell
sort
success
identifi
three
mab
potent
neutral
activ
pseudo
live
ebov
epitop
map
competit
bind
singleparticl
em
reconstruct
sitedirect
mutagenesi
reveal
bind
novel
overlap
epitop
span
glycan
cap
head
subdomain
approach
rbd
subunit
hand
bind
epitop
partial
overlap
glycan
cap
orient
toward
upper
surfac
chalic
distinct
contrast
mab
bind
similar
adjac
epitop
newli
isol
mab
complet
partial
independ
complement
live
ebov
neutral
particular
novel
mab
abl
achiev
close
inhibit
live
ebov
presenc
complement
plateau
inhibit
furthermor
treatment
mab
individuali
provid
partial
signific
protect
diseas
progress
mous
model
ebov
infect
collect
result
suggest
recogn
novel
epitop
subunit
potent
neutral
activ
could
serv
promis
candid
prophylact
therapeut
intervent
ebola
viru
infect
gener
isol
mab
gpdm
immun
macaqu
use
recombin
gpdm
delet
mucinlik
domain
mld
transmembran
domain
immun
two
rhesu
macaqu
larg
due
earlier
studi
indic
bulki
mld
highli
variabl
abl
shield
critic
receptor
bind
domain
rbd
ebola
viru
glycoprotein
enhanc
promot
matur
antibodi
respons
eight
consecut
immun
perform
intramuscular
rout
interv
blood
sampl
collect
evalu
antibodi
bind
neutral
activ
anim
mount
strong
antibodi
bind
activ
measur
elisa
well
neutral
activ
use
pseudoviru
bear
glycoprotein
ebov
mayinga
strain
supplementari
fig
particular
appear
higher
neutral
activ
vs
id
valu
supplementari
fig
therefor
chosen
peripher
blood
mononuclear
cell
pbmc
isol
gpdmspecif
singl
memori
b
cell
igg
fac
supplementari
fig
amplifi
variabl
region
immunoglobulin
heavi
light
chain
gene
vh
vl
optim
nest
polymeras
chain
reaction
pcr
total
pair
vh
vl
sequenc
sort
singl
b
cell
obtain
fuse
constant
region
fragment
human
gener
bival
fulllength
chimer
mab
confirm
sequenc
fulllength
heavi
light
chain
plasmid
cotransfect
cell
product
purif
character
mab
bind
neutral
activ
pseudo
live
ebola
viru
infect
first
analyz
bind
activ
isol
mab
four
differ
form
ebov
gp
includ
recombin
gpdm
sgp
gpcl
well
gp
delet
mld
gpdmuc
express
surfac
cell
among
total
mab
success
isol
produc
detect
bind
gpdm
measur
elisa
demonstr
strong
bind
affin
compar
control
mab
mere
detect
threshold
fig
similar
differ
also
found
bind
gpdmuc
express
surfac
cell
suggest
bind
mab
independ
mld
like
bound
strongli
sgp
indic
epitop
locat
nterminu
subunit
gpdm
sgp
share
amino
acid
residu
interestingli
maintain
strong
bind
glycan
cap
miss
gpcl
fail
suggest
recogn
epitop
distinct
genet
mab
uniqu
vh
vl
sequenc
although
share
homolog
sequenc
throughout
except
sequenc
vh
tabl
gene
famili
mab
quit
diverg
vh
v
h
v
h
v
h
v
h
vl
v
v
variabl
degre
diverg
rhesu
macaqu
germlin
sequenc
tabl
degre
human
recombin
fulllength
mab
rang
analyz
amino
acid
sequenc
compar
human
immunoglobulin
gene
use
germlin
index
neutral
activ
test
suscept
cell
ebola
pseudoviru
bear
surfac
glycoprotein
ebov
sudv
bdbv
restv
tafv
fig
tabl
consist
bind
activ
demonstr
potent
neutral
ebov
mayinga
strain
ic
valu
rang
gml
show
neglig
effect
fig
tabl
like
abl
reach
ic
plateau
prematur
around
inhibit
despit
increas
concentr
fig
consist
earlier
report
furthermor
differ
slope
auc
also
found
among
isol
control
mab
suggest
differ
mab
demonstr
differ
potenc
may
exert
neutral
activ
differ
mechan
tabl
none
isol
mab
demonstr
crossneutr
activ
remain
speci
ebolavirus
sudv
bdbv
restv
tafv
pseudoviru
bear
envelop
glycoprotein
marv
vsv
display
level
crossact
sudv
strain
previous
report
crossbind
found
gpdm
sudv
bdbv
marv
supplementari
fig
furthermor
also
show
potent
neutral
live
ebov
viru
fig
tabl
particular
similar
ic
concentr
presenc
absenc
complement
suggest
neutral
activ
larg
independ
complement
contrast
like
mab
control
requir
presenc
complement
optim
neutral
although
significantli
higher
neutral
activ
found
fig
kinet
competit
bind
isol
mab
measur
spr
observ
differ
neutral
activ
pseudo
live
ebola
viru
could
due
differ
bind
affin
epitop
recogn
test
hypothesi
measur
bind
kinet
antigenbind
fragment
fab
recombin
gpdm
sgp
gpcl
surfac
plasmon
reson
spr
shown
fig
differenti
bind
recombin
protein
consist
analyz
elisa
fig
furthermor
estim
bind
affin
gpdm
appear
correl
neutral
activ
tabl
demonstr
strongest
bind
affin
k
nm
intermedi
k
nm
weakest
k
nm
consist
earlier
report
demonstr
higher
bind
affin
k
nm
mab
isol
henc
also
show
stronger
neutral
activ
howev
outlier
perhap
due
uniqu
unusu
neutral
curv
inhibitori
activ
appear
earli
rel
lower
concentr
plateau
prematur
despit
increas
concentr
fig
contrast
bind
affin
sgp
nt
seem
follow
trend
neutral
weakest
neutral
mab
isol
show
highest
affin
k
nm
sgp
demonstr
intermedi
k
nm
weakest
k
nm
interestingli
remov
glycan
cap
gpdm
thermolysin
gpcl
dramat
increas
bind
k
nm
effect
k
nm
tabl
result
highlight
bind
affin
membran
associ
gpdm
gpcl
secret
sgp
form
gp
may
contribut
differenti
neutral
activ
among
isol
mab
particular
ebov
entri
requir
cleavag
envelop
glycoprotein
endosom
favor
bind
gpcl
gpdm
suggest
possibl
enhanc
inhibitori
effect
mab
process
viral
entri
went
determin
epitop
isol
mab
gpdm
pairwis
competit
use
spr
specif
pair
test
fab
sequenti
appli
purifi
gpdm
coval
immobil
sensor
chip
monitor
addit
bind
determin
whether
two
mab
recogn
separ
close
situat
epitop
shown
fig
strongli
partial
hand
strongli
compet
fig
convers
strongli
compet
partial
fig
result
clearli
indic
recogn
overlap
epitop
two
overlap
epitop
appear
close
locat
grossli
distinct
recogn
singl
particl
em
reconstruct
gpdm
complex
fab
determin
epitop
precis
manner
neg
stain
singleparticl
em
reconstruct
perform
gpdm
complex
fab
fab
ad
excess
gpdm
purifi
sizeexclus
chromatographi
subject
stain
em
analys
fig
supplementari
fig
supplementari
tabl
structur
complex
show
antibodi
bound
novel
epitop
within
center
gpdm
chalic
perpendicularli
expect
plane
membran
make
contact
region
span
glycan
cap
cyan
head
blue
subdomain
subunit
fig
supplementari
fig
hand
bound
vicin
glycan
cap
angl
approach
much
less
steep
fig
supplementari
fig
compar
bind
site
gener
hybrid
map
base
structur
inform
obtain
previous
publish
elsewher
shown
fig
bind
site
locat
next
closer
inner
chalic
subunit
contrari
bind
site
locat
opposit
side
glycan
cap
orient
toward
upper
surfac
chalic
fig
shown
previous
control
bound
base
gpdm
result
consist
epitop
map
studi
conduct
provid
clear
three
dimension
understand
locat
distribut
epitop
recogn
subunit
epitop
map
sitedirect
mutagenesi
confirm
epitop
inform
obtain
conduct
sitedirect
mutagenesi
ebov
gpdmuc
mayinga
strain
base
structur
inform
well
previous
publish
studi
shown
confer
resist
control
mab
total
singl
mutant
clone
gener
one
base
four
head
thirteen
glycan
cap
subunit
five
subunit
mutat
detriment
effect
bind
minim
effect
rest
mab
test
next
studi
whether
reduct
bind
could
confer
resist
mab
neutral
context
pseudoviru
end
pseudovirus
bear
repres
mutat
gener
subject
standard
neutral
test
fig
consist
bind
analysi
mutat
head
result
complet
resist
neutral
least
increas
ic
compar
wild
type
similarli
mutat
glycan
cap
subunit
also
render
pseudoviru
complet
resist
well
respect
need
note
set
mutat
notic
crosseffect
neutral
activ
mab
limit
within
differ
wild
type
like
due
indirect
consequ
fig
nevertheless
result
confirm
bind
novel
epitop
locat
glycan
cap
head
subdomain
approach
rbd
inner
chalic
hand
bind
overlap
epitop
glycan
cap
toward
upper
surfac
chalic
post
attach
inhibit
partial
interfer
receptor
bind
determin
potenti
step
inhibit
appli
test
mab
pseudovirus
target
cell
two
separ
time
scale
one
incub
pseudovirus
first
h
viru
attach
cell
allow
viru
attach
cell
first
h
ad
test
mab
elev
temperatur
initi
viru
entri
reason
test
mab
inhibit
viru
attach
cell
surfac
reduct
luciferas
activ
would
detect
former
experi
hand
test
mab
inhibit
step
viru
attach
reduct
luciferas
activ
would
detect
case
shown
fig
abl
reduc
luciferas
activ
case
suggest
inhibit
step
viru
attach
consist
earlier
report
posit
control
also
inhibit
postattach
step
neg
control
fail
case
fig
epitop
locat
glycan
cap
head
subdomain
approach
rbd
may
exert
neutral
activ
attach
interf
gpcl
bind
cellular
receptor
test
hypothesi
immobil
gpcl
sensor
chip
follow
inject
separ
reach
bind
steadyst
domain
c
inject
compar
bind
kinet
without
test
mab
shown
fig
protect
efficaci
mous
model
ebov
infect
determin
protect
efficaci
isol
mab
vivo
infect
mice
intraperiton
inject
ip
dose
ld
mouseadapt
ebov
administ
either
day
post
infect
control
anim
receiv
pb
succumb
viru
averag
time
death
day
contrast
mab
treatment
significantli
increas
surviv
infect
mice
pvalu
highest
surviv
rate
anim
group
treat
pvalu
h
pvalu
tabl
interestingli
degre
weight
chang
correl
protect
efficaci
fact
two
group
highest
surviv
also
highest
weight
loss
supplementari
fig
discuss
unpreced
ebov
outbreak
west
africa
affect
peopl
previous
record
outbreak
combin
highlight
threat
global
health
signific
process
made
therapeut
vaccin
ebov
licens
product
current
avail
combin
monoclon
antibodi
repres
one
specif
promis
therapeut
modal
one
cocktail
zmapp
demonstr
safeti
efficaci
nonhuman
primat
well
encourag
result
compassion
use
human
although
develop
clinic
applic
requir
studi
antibodi
togeth
publish
one
direct
sever
vulner
site
surfac
gp
includ
glycan
cap
mucinlik
domain
base
gp
interact
neutral
mab
howev
target
overlap
epitop
base
gp
neutral
neutral
absenc
complement
bind
glycan
cap
mucinlik
dom
ain
recent
studi
isol
larg
number
mab
convalesc
individu
neutral
activ
target
addit
site
gp
studi
aim
identifi
neutral
mab
target
addit
site
gp
ebola
viru
identifi
sequenti
immun
chines
rhesu
macaqu
recombin
gpdm
antigenspecif
singl
b
cell
sort
success
isol
character
three
mab
potent
neutral
activ
pseudo
live
ebov
epitop
map
differenti
bind
singleparticl
em
reconstruct
sitedirect
mutagenesi
reveal
bind
novel
overlap
epitop
span
glycan
cap
head
subdomain
approach
rbd
inner
chalic
hand
bind
overlap
epitop
glycan
cap
orient
toward
upper
surfac
chalic
distinct
contrast
mab
bind
similar
adjac
epitop
newli
isol
mab
complet
partial
independ
complement
live
ebov
neutral
particular
novel
mab
abl
achiev
close
inhibit
live
ebov
presenc
complement
plateau
inhibit
furthermor
treatment
mab
provid
partial
signific
protect
diseas
progress
mous
model
ebov
infect
collect
result
suggest
recogn
novel
epitop
tabl
impact
mutant
residu
mab
bind
surfac
express
gpdmuc
indic
least
reduct
fluoresc
intens
compar
wild
type
indic
complet
abolish
antibodi
bind
potent
neutral
activ
could
serv
promis
candid
prophylact
therapeut
intervent
ebola
viru
infect
believ
neutral
mab
identifi
repres
new
arsen
ebov
infect
potent
protect
mab
recogn
overlap
epitop
within
core
region
encompass
rbd
base
previou
studi
suggest
region
may
conceal
proteolysi
endosom
cathepsin
receptor
bind
bind
well
neutral
profil
indic
region
contain
open
spot
antibodi
bind
neutral
earli
step
viral
entri
exact
underli
mechan
requir
investig
appear
exert
neutral
activ
interf
gp
bind
receptor
may
lead
affect
subsequ
fusion
viral
cellular
membran
hypothesi
support
mutagenesi
studi
mutant
viru
residu
locat
edg
rbd
critic
bind
becam
resist
fig
tabl
howev
mechan
action
far
less
clear
despit
overlap
epitop
protect
activ
mous
model
much
less
effect
perhap
due
differ
exact
epitop
test
mab
appli
pseudoviru
cell
attach
b
competit
bind
test
mab
immobil
gpcl
chip
block
efficaci
determin
control
mab
respect
affin
approach
angl
fcmediat
function
antibodi
gp
note
import
recogn
neutral
activ
alway
translat
protect
activ
mous
model
mous
model
ca
nt
alway
predict
monkey
model
ultim
test
conduct
human
meaning
protect
activ
could
evalu
determin
case
would
interest
studi
whether
combin
newli
isol
mab
could
synergist
effect
provid
stronger
broader
neutral
protect
activ
wildtyp
mutant
ebov
although
current
dataset
ebov
show
limit
degre
sequenc
variat
mean
suggest
viru
remain
unchang
long
run
given
wide
spread
sever
anim
speci
continu
zoonot
introduct
rapid
transmiss
within
human
popul
potent
neutral
mab
identifi
novel
epitop
specif
advantag
posit
gener
optim
nextgener
therapeut
antibodi
cocktail
ebov
infect
ethic
statement
rhesu
macaqu
experi
carri
strict
complianc
chines
govern
rule
regul
anim
health
welfar
experiment
protocol
immun
blood
collect
guangzhou
institut
biomedicin
health
chines
academi
scienc
approv
institut
anim
care
use
committe
mice
experi
perform
nation
microbiolog
laboratori
winnipeg
canada
anim
experi
approv
anim
care
committe
canadian
scienc
center
human
anim
health
accord
guidelin
outlin
canadian
council
anim
care
immun
rhesu
macaqu
year
old
chines
rhesu
macaqu
macaca
mulatta
immun
intramuscularli
everi
week
g
recombin
ebov
gp
devoid
mucinlik
transmembran
domain
gpdm
deriv
guinean
patient
genbank
access
number
identifi
outbreak
first
two
dose
formul
alum
adjuv
imject
alum
thermo
scientif
subsequ
dose
recombin
gpdm
plasma
peripher
blood
mononuclear
cell
pbmc
collect
th
immun
evalu
bind
neutral
activ
use
sort
singl
b
cell
amplifi
immunoglobulin
heavi
light
chain
gene
vh
vl
nest
polymeras
chain
reaction
pcr
anim
hous
anim
experiment
center
guangzhou
institut
biomedicin
health
chines
academi
scienc
gpcl
deriv
guinean
patient
genbank
access
number
identifi
outbreak
share
approxim
homolog
zair
strain
democrat
republ
congo
gabon
specif
gpdm
delet
mucinlik
mld
transmembran
domain
residu
clone
vector
invitrogen
previous
describ
protein
secret
purif
signal
peptid
tag
ad
nterminu
cterminu
protein
respect
transfect
viru
amplif
perform
accord
manufactur
instruct
invitrogen
solubl
gpdm
produc
cell
invitrogen
harvest
cultur
supernat
metal
affin
chromatographi
use
histrap
hp
column
ge
healthcar
purifi
gel
filtrat
hiload
superdex
pg
column
ge
healthcar
gpcl
glycan
cap
remov
gener
treat
gpdm
mgml
thermolysin
sigma
mgml
hepesm
buffer
mm
hepe
mm
morpholinepropanesulfon
acid
mm
nacl
ph
h
cleavag
stop
addit
edta
final
concentr
mm
gene
encod
sgp
residu
clone
baculoviru
transfer
vector
invitrogen
infram
ntermin
signal
peptid
secret
c
terminu
purif
transfect
viru
amplif
perform
accord
manufactur
instruct
invitrogen
recombin
protein
produc
infect
suspens
cultur
cell
invitrogen
day
recov
cell
supernat
metal
affin
chromatographi
use
histrap
hp
column
ge
healthcar
purifi
gel
filtrat
chromatographi
use
ficollhypaqu
ge
healthcar
separ
subsequ
stain
variou
cell
surfac
marker
identifi
enrich
sort
singl
antigenspecif
memori
b
cell
igg
gpdmposit
use
fac
aria
ii
flow
cytomet
bd
bioscienc
usa
sort
singl
b
cell
well
plate
revers
transcrib
variabl
region
immunoglobulin
heavi
light
chain
gene
vh
vl
amplifi
nest
pcr
use
optim
version
previous
describ
protocol
brief
revers
transcript
reaction
perform
mixtur
superscript
iii
revers
transcriptas
rnase
dntp
invitrogen
primer
specif
igg
igm
iga
igd
ige
incub
min
cdna
amplifi
pcr
appropri
primer
pair
l
reaction
min
follow
measur
antibodi
crossreact
addit
ebolaviru
speci
costar
halfarea
high
bind
assay
plate
corn
coat
overnight
ng
ebov
gpdtm
ebov
sgp
sudv
gpdtm
bdbv
gpdtm
marv
gpdtm
ibt
bioservic
usa
dilut
l
pb
respect
plate
block
h
skim
milkpb
test
mab
serial
dilut
skim
milkpb
lwell
incub
h
wash
time
lwell
secondari
antibodi
horseradish
peroxidas
hrp
conjug
goat
antihuman
igg
kpl
usa
ad
gml
skim
milkpb
incub
h
follow
wash
lwell
hrp
substrat
tmb
thermofish
ad
incub
room
temperatur
min
dark
plate
read
versamax
micropl
reader
molecular
devic
use
softmax
pro
softwar
result
report
optic
densiti
measur
nm
everi
step
plate
seal
seal
film
excel
scientif
total
five
differ
speci
ebola
pseudoviru
ebov
sudv
bdbv
restv
tafv
gener
cotransfect
human
immunodefici
viru
backbon
express
firefli
luciferas
express
vector
invitrogen
encod
fulllength
glycoprotein
ebola
speci
cell
atcc
viral
supernat
collect
h
later
viral
titer
measur
luciferas
activ
rel
light
unit
brightglo
luciferas
assay
vector
system
promega
bioscienc
mutant
ebov
glycoprotein
gener
sitedirect
mutagenesi
express
vector
encod
wild
type
ebov
glycoprotein
mayinga
strain
follow
manufactur
instruct
agil
mutant
clone
confirm
sequenc
control
envelop
glycoprotein
marburg
viru
marv
human
immunodefici
viru
vesicular
stomat
viru
vsv
correspond
pseudovirus
made
manner
control
mab
includ
human
neutral
mab
mab
previous
isol
neutral
mab
ebov
neutral
assay
perform
incub
pseudoviru
serial
dilut
purifi
test
mab
h
cell
per
well
atcc
infect
triplic
virusantibodi
mixtur
neutral
activ
test
mab
determin
luciferas
activ
hour
infect
present
ic
ic
slope
calcul
doserespons
inhibit
function
graphpad
prism
graphpad
softwar
inc
area
curv
auc
determin
matlab
mathwork
fluoresc
neutral
assay
perform
tissu
cultur
plate
corn
previous
describ
viru
ebovmayegfp
passag
incub
serial
dilut
test
mab
rang
gml
h
plain
dmem
without
complement
sigma
cell
atcc
confluenc
infect
triplic
virusantibodi
mixtur
moi
tcid
per
cell
infect
carri
h
co
inoculum
remov
replac
fb
plate
incub
h
fluoresc
intens
gfp
measur
use
synergi
ht
micropl
reader
biotek
median
ebov
neutral
concentr
calcul
base
fourparamet
curv
fit
ebovmayegfp
fluoresc
curv
use
graphpad
prism
scientif
report
doi
antibodi
bind
kinet
epitop
map
competit
receptor
measur
spr
bind
kinet
affin
mab
three
purifi
ebov
antigen
gpdm
sgp
gpcl
analyz
surfac
plasmon
reson
spr
biacor
ge
healthcar
purifi
solubl
antigen
coval
immobil
sensor
chip
via
amin
group
mm
sodium
acet
buffer
ph
final
ru
around
mab
cleav
antigenbind
fragment
fab
incub
proteas
lysc
sigma
ratio
igg
lysc
ww
mm
edta
mm
triscl
ph
hour
spr
experi
run
flow
rate
mlmin
pb
buffer
sensogram
fit
bind
model
bia
evalu
softwar
ge
healthcar
epitop
map
two
differ
fab
inject
sequenti
monitor
addit
bind
activ
determin
whether
two
mab
recogn
separ
close
situat
epitop
competit
experi
domain
c
gpcl
immobil
sensor
chip
via
amin
group
final
ru
around
antibodi
inject
onto
chip
second
reach
bind
steadyst
inject
second
block
efficaci
determin
comparison
respons
unit
without
antibodi
preincub
produc
purifi
previous
report
fab
test
mab
molar
ratio
h
form
complex
purifi
size
exclus
chromatographi
four
microlit
gpdmfab
complex
concentr
mgml
appli
onto
glow
discharg
continu
carbon
grid
beij
xinx
braim
technolog
co
ltd
enough
materi
adsorb
grid
treat
filter
paper
remov
excess
sampl
immedi
wash
twice
incub
l
uranyl
acet
ua
solut
addit
grid
treat
filter
paper
remov
ua
airdri
room
temperatur
examin
fei
tecnai
electron
microscop
equip
feg
filament
oper
acceler
voltag
use
nomin
magnif
pixel
size
nm
electron
microscopi
imag
process
imag
record
use
gatan
k
k
ccd
camera
exposur
dose
e
defocu
rang
use
softwar
packag
use
pick
particl
gener
initi
model
sever
round
referencefre
classif
classif
perform
select
good
particl
use
program
select
particl
use
autorefin
reconstruct
symmetri
impos
resolut
final
map
calcul
use
golden
standard
fourier
shell
correl
valu
em
map
relat
materi
deposit
em
data
bank
access
code
better
interpret
em
map
crystal
structur
ebov
gpdm
pdb
access
number
marburg
viru
mab
fab
pdb
access
number
fit
em
densiti
map
program
situ
ebov
gpdtm
fab
em
map
emdb
access
number
fit
em
densiti
map
use
chimera
protect
efficaci
mab
mice
balbc
mice
week
old
femal
weigh
g
randomli
assign
group
mice
mice
challeng
intraperiton
inject
ip
dose
ld
mouseadapt
ebov
l
dmem
mab
given
ip
day
post
infect
g
individu
mab
per
mous
control
group
given
volum
pb
anim
monitor
sign
diseas
surviv
weight
chang
day
surviv
monitor
addit
day
statist
analysi
ebola
pseudoviru
neutral
experi
halfmaxim
nineti
percent
inhibitori
concentr
ic
ic
well
inhibitori
slope
mab
calcul
use
doserespons
inhibit
model
graphpad
prism
graphpad
softwar
inc
area
curv
auc
mab
determin
matlab
mathwork
ebov
live
viru
neutral
experi
median
neutral
concentr
mab
calcul
base
fourparamet
curv
fit
ebovmayegfp
fluoresc
curv
use
graphpad
prism
mice
challeng
protect
experi
differ
surviv
calcul
group
compar
receiv
pb
use
logrank
mantelcox
test
graphpad
prism
mean
p
mean
p
respect
